Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: PF-07220060
Drug: letrozole
Drug: abemaciclib
Drug: palbociclib
Drug: ribociclib

First Posted Date: 2025-01-07

Last Posted Date: 2025-06-22

Lead Sponsor: Pfizer

Target Recruit Count: 1020

Registration Number: NCT06760637

Locations: 🇺🇸
Ironwood Cancer & Research Centers, Scottsdale, Arizona, United States
🇺🇸
Highlands Oncology, Rogers, Arkansas, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States

and more 231 locations

A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market

Not yet recruiting

Conditions: Pneumococcal Immunization
Safety

Interventions: Biological: Pneumococcal 20-valent conjugate vaccine

First Posted Date: 2025-01-06

Last Posted Date: 2025-07-02

Lead Sponsor: Pfizer

Target Recruit Count: 660

Registration Number: NCT06760208

Locations: 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Phase 3

Recruiting

Conditions: Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung (NSCLC)

Interventions: Drug: Sigvotatug Vedotin
Drug: Pembrolizumab

First Posted Date: 2025-01-03

Last Posted Date: 2025-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 714

Registration Number: NCT06758401

Locations: 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸
BRCR Global, Plantation, Florida, United States
🇺🇸
Hope and Healing Cancer Services, New Lenox, Illinois, United States

and more 6 locations

Secondary Databased Post-marketing Surveillance Study of BNT162b2

Completed

Conditions: COVID-19
SARS-CoV-2

Interventions: Biological: Tozinameran (BNT162b2)
Biological: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)
Biological: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

First Posted Date: 2024-12-19

Last Posted Date: 2025-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06743334

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2024-12-16

Last Posted Date: 2025-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 3

Registration Number: NCT06735742

Locations: 🇯🇵
Pfizer, Tokyo, Japan

A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.

Not yet recruiting

Conditions: Prostate Cancer

First Posted Date: 2024-12-13

Last Posted Date: 2025-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 104

Registration Number: NCT06733337

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

Phase 2

Active, not recruiting

Conditions: Obesity

Interventions: Drug: PF-07976016
Drug: Placebo

First Posted Date: 2024-12-05

Last Posted Date: 2025-06-26

Lead Sponsor: Pfizer

Target Recruit Count: 232

Registration Number: NCT06717425

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Clinical & Translational Research Center, Aurora, Colorado, United States
🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

and more 34 locations

A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: PF-07264660
Other: Placebo

First Posted Date: 2024-12-02

Last Posted Date: 2025-07-01

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06712082

Locations: 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07258669
Drug: Itraconazole

First Posted Date: 2024-11-27

Last Posted Date: 2025-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT06706869

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸
Research Centers of America, Hollywood, Florida, United States

A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tafamidis 61 mg free acid tablet (Test)
Drug: Tafamidis 61 mg free acid capsule (Reference)

First Posted Date: 2024-11-26

Last Posted Date: 2025-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT06705569

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy